Open Access

Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1

  • Authors:
    • Boren Tian
    • Yaxuan Wu
    • Xiaoyun Du
    • Yan Zhang
  • View Affiliations

  • Published online on: October 29, 2024     https://doi.org/10.3892/ijmm.2024.5451
  • Article Number: 10
  • Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma malignancy exhibits significant heterogeneity, comprising both osteosarcoma stem cells (OSCs) and non‑OSCs. OSCs demonstrate increased resistance to chemotherapy due to their distinctive cellular and molecular characteristics. Alterations in mitochondrial morphology and homeostasis may enhance chemoresistance by modulating metabolic and regulatory processes. However, the relationship between mitochondrial homeostasis and chemoresistance in OSCs remains to be elucidated. The present study employed high‑resolution microscopy to perform multi‑layered image reconstructions for a quantitative analysis of mitochondrial morphology. The results indicated that OSCs exhibited larger mitochondria in comparison with non‑OSCs. Furthermore, treatment of OSCs with cisplatin (CIS) or doxorubicin (DOX) resulted in preserved mitochondrial morphological stability, which was not observed in non‑OSCs. This finding suggested a potential association between mitochondrial homeostasis and chemoresistance. Further analysis indicated that dynamin‑related protein 1 (DRP1) might play a pivotal role in maintaining the stability of mitochondrial homeostasis in OSCs. Depletion of DRP1 resulted in the disruption of mitochondrial stability when OSCs were treated with CIS or DOX. Additionally, knocking out DRP1 in OSCs led to a reduction in chemoresistance. These findings unveil a novel mechanism underlying chemoresistance in osteosarcoma and suggest that targeting DRP1 could be a promising therapeutic strategy to overcome chemoresistance in OSCs. This provided valuable insights for enhancing treatment outcomes among patients with osteosarcoma.

Related Articles

Journal Cover

January-2025
Volume 55 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tian B, Wu Y, Du X and Zhang Y: Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1. Int J Mol Med 55: 10, 2025.
APA
Tian, B., Wu, Y., Du, X., & Zhang, Y. (2025). Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1. International Journal of Molecular Medicine, 55, 10. https://doi.org/10.3892/ijmm.2024.5451
MLA
Tian, B., Wu, Y., Du, X., Zhang, Y."Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1". International Journal of Molecular Medicine 55.1 (2025): 10.
Chicago
Tian, B., Wu, Y., Du, X., Zhang, Y."Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1". International Journal of Molecular Medicine 55, no. 1 (2025): 10. https://doi.org/10.3892/ijmm.2024.5451